Fiche publication
Date publication
janvier 2021
Journal
Patient preference and adherence
Auteurs
Membres identifiés du Cancéropôle Est :
Pr TROJAK Benoît
Tous les auteurs :
Chappuy M, Meroueh F, Trojak B, Bachellier J, Bendimerad P, Kosim M, Hjelmström P, Nubukpo P, Brousse G, Rolland B
Lien Pubmed
Résumé
Extended-release buprenorphine (XR-BUP) covers a range of formulations of buprenorphine-based treatments for opioid use disorder (OUD) that release the medication over a period of one week, one month, or six months. OUD is particularly prevalent among incarcerated populations, and previous findings have shown that incarcerated subjects were not less interested in XR-BUP than non-incarcerated subjects. However, no study has ever investigated whether the factors of interest in XR-BUP were similar in incarcerated and non-incarcerated populations.
Mots clés
buprenorphine, opioid use disorder, preferences, prison
Référence
Patient Prefer Adherence. 2021 ;15:1259-1267
